Donald Trump is executing a shock and awe strategy, burying the public in a smoky cloud of flamboyant proposals. Some, like ...

Although RMD has re-rated from its share price low of around $21.50 in October 2023, it has only just surpassed its all-time ...

Weight-loss drugs are transforming health care and Wall Street, but exciting prospects don’t necessarily mean a company is a good investment.

During a Senate HELP Committee hearing, RFK Jr. stated that President Trump is dedicated to bringing drug manufacturing "back ...

We recently compiled a list of the Jim Cramer Shed Light on These 9 Stocks. In this article, we are going to take a look at ...

The widespread acceptance of the so-called GLP-1 drugs, Zepbound by Eli Lilly and Wegovy by Novo Nordisk, for weight loss has created a game-changing dynamic for the overall health of the 72% of ...

Luckily, the hiring process proceeded smoothly and Charles van Zyl joined as chief executive from Belgian pharma company UCB (BE:UCB) in 2023, while Joerg Hornstein has been in post as chief finance ...

Cardinal Health had $210 billion in pharmaceutical and specialty drugs sales in fiscal 2024, up 11% year-over-year, helped in large part by GLP-1 sales. In Q4, segment sales rose 13% to $55 billion, ...

President Donald Trump is executing a shock and awe strategy, burying the public in a smoky cloud of flamboyant proposals. Some, like ending birthright citizenship, are quickly slapped down in ...

Scholar Rock submitted its BLA of apitegromab for the treatment of patients with Spinal Muscular Atrophy with a request for ...

Donald Trump is executing a shock and awe strategy, burying the public in a smoky cloud of flamboyant proposals. Some, like ending birthright citizenship, ...

Viking Therapeutics VKTX is set to report fourth-quarter and full-year 2024 earnings on Feb. 5, after market close. Since the ...